Joly, Bertrand

Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients

Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 111

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Guilhot, F., Rigal-Huguet, F., Guilhot, J., Guerci-Bresler, A.-P., Maloisel, F., Rea, D., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 30

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 17